[go: up one dir, main page]

NO20010844D0 - Regulation of substrate activity - Google Patents

Regulation of substrate activity

Info

Publication number
NO20010844D0
NO20010844D0 NO20010844A NO20010844A NO20010844D0 NO 20010844 D0 NO20010844 D0 NO 20010844D0 NO 20010844 A NO20010844 A NO 20010844A NO 20010844 A NO20010844 A NO 20010844A NO 20010844 D0 NO20010844 D0 NO 20010844D0
Authority
NO
Norway
Prior art keywords
regulation
substrate activity
activity
substrate
Prior art date
Application number
NO20010844A
Other languages
Norwegian (no)
Other versions
NO20010844L (en
Inventor
Barbara P Wallner
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of NO20010844D0 publication Critical patent/NO20010844D0/en
Publication of NO20010844L publication Critical patent/NO20010844L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20010844A 1998-08-21 2001-02-19 Regulation of substrate activity NO20010844L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9737698P 1998-08-21 1998-08-21
PCT/US1999/018315 WO2000010549A1 (en) 1998-08-21 1999-08-13 Regulation of substrate activity

Publications (2)

Publication Number Publication Date
NO20010844D0 true NO20010844D0 (en) 2001-02-19
NO20010844L NO20010844L (en) 2001-04-23

Family

ID=22263045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010844A NO20010844L (en) 1998-08-21 2001-02-19 Regulation of substrate activity

Country Status (9)

Country Link
EP (1) EP1104293A1 (en)
JP (1) JP2002523365A (en)
KR (1) KR20010079669A (en)
AU (1) AU5480199A (en)
BR (1) BR9913153A (en)
CA (1) CA2339537A1 (en)
IL (1) IL141471A0 (en)
NO (1) NO20010844L (en)
WO (1) WO2000010549A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743996B2 (en) 1997-09-29 2002-02-14 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
JP2002513762A (en) 1998-05-04 2002-05-14 ポイント セラピューティクス， インコーポレイテッド Hematopoietic stimulation
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
JP2003500360A (en) * 1999-05-25 2003-01-07 ポイント セラピューティクス， インコーポレイテッド Anticancer agents containing boroproline compounds
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DE60134251D1 (en) 2000-09-18 2008-07-10 Sanos Bioscience As USE OF GLP-2 PEPTIDES
EP1349576B1 (en) 2001-01-02 2011-11-23 IMTM GmbH Combined use of enzyme inhibitors for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with follicular and epidermal hyperkeratosis and reinforced keratinocyte proliferation
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
EP1399471B1 (en) * 2001-06-27 2008-01-30 Probiodrug AG Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
EP2316470A3 (en) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
CA2466870A1 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
JP2005527504A (en) 2002-02-28 2005-09-15 プロシディオン・リミテッド DPIV inhibitors based on glutaminyl
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
NZ568459A (en) 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050070531A1 (en) 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
CN1292747C (en) * 2003-09-16 2007-01-03 广东省心血管病研究所 Compound formulation for treating hypertension
JP5707014B2 (en) 2003-10-15 2015-04-22 プロビオドルグ エージー Use of glutaminyl and glutamate cyclase effectors
EP1686994A2 (en) * 2003-11-17 2006-08-09 Novartis AG Use of dipeptidyl peptidase iv inhibitors
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (en) 2005-09-16 2009-02-04 武田药品工业株式会社 Process for preparing pyrimidinedione derivatives
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
CN103323606A (en) 2006-04-11 2013-09-25 艾尼纳制药公司 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
JP2013523819A (en) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド GPR119 receptor modulators and treatment of disorders related thereto
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3106173A1 (en) * 2011-11-22 2016-12-21 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
KR20180006881A (en) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. Methods for the treatment of nonalcoholic fatty liver disease and / or fat dystrophy
KR20200036808A (en) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. PPARγ agonist for the treatment of advanced nuclear paralysis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124371T2 (en) * 1990-04-14 1997-06-12 New England Medical Center Inc TYPE IV DIPEPTIDYL AMINOPEPTIDASE INHIBITORS
ATE349461T1 (en) * 1991-10-22 2007-01-15 New England Medical Center Inc TYPE IV DIPEPTIDYL-AMINOPEPTIDASE INHIBITORS
AU4794393A (en) * 1992-07-31 1994-03-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
WO1995011689A1 (en) * 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
AU1616499A (en) * 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
DE69905038T2 (en) * 1998-06-05 2003-06-05 Point Therapeutics, Inc. CYCLIC BOROPROLIN COMPOUNDS

Also Published As

Publication number Publication date
BR9913153A (en) 2001-05-15
WO2000010549A1 (en) 2000-03-02
AU5480199A (en) 2000-03-14
JP2002523365A (en) 2002-07-30
KR20010079669A (en) 2001-08-22
CA2339537A1 (en) 2000-03-02
IL141471A0 (en) 2002-03-10
EP1104293A1 (en) 2001-06-06
NO20010844L (en) 2001-04-23

Similar Documents

Publication Publication Date Title
NO20010844D0 (en) Regulation of substrate activity
CY2012029I2 (en) NEW FORM OF 5-OMEPRAZOLE
ID29021A (en) COMPOSITION OF CONTROLLED GALANTAMINA
EE9900575A (en) Regulation of quinolate phosphoribosyl transferase expression
NO20010899L (en) Improvement of adverse apomorphine effects
DE69925229D1 (en) coating structure
FI980387A0 (en) For the purposes of this Regulation
NO20001847L (en) New use of compounds for anti-itch activity
FI974023A0 (en) Taetningskonstruktion Foer suglaogan av en sugvals i en pappersmaskin / en kartongmaskin
EP1148107A4 (en) BIOLOGICALLY ACTIVE COATED GRAINS
ID24677A (en) COMBINATION OF FUNICIDAL ACTIVE COMPOUNDS
ID28032A (en) TRICICLIC OF PIPERIDIN-Δ3-AS ANTAGONIS-α2
ID24327A (en) PRODUCTION OF AVERMEKTIN COMPOUNDS
FI980092A0 (en) Regulation and order of the harvester
FI973312A0 (en) Foerfarande Foer indicering av en abonnent i en kedjad V5-aslutning
NO993549D0 (en) Imino-aza-anthracycline derivatives for the treatment of amyloidosis
FI973582A0 (en) Maetning av faedningsmarginal i radiosystem
NO20014845D0 (en) Use of arylalkanoylpyridazines
FI973860A0 (en) Foerfarande Foer saekerstaellande av noedkommunikation i en kedjad V5-aslutning
FI972847A0 (en) Foerfarande Foer hantering av aonga i en fibreringsprocess
UA25690A (en) METHOD OF OBTAINING THE ACTIVE SUBSTRATE
ID29414A (en) TREATMENT OF DEPRESSION
FI104278B1 (en) Support construction of balcony
FI974311A0 (en) Foerfarande Foer centralisering av abonnenter i en lokalcentral
FI973311A0 (en) Foerfarande Foer foermedling av protoken Foer V5-enslutningar i en kedjad V5-anslutning

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application